Person:
YOLDEMİR, AHMET TEVFİK

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

YOLDEMİR

First Name

AHMET TEVFİK

Name

Filters

2009 - 200912010 - 20192
Reset filters

Settings

Subject: CARDIOVASCULAR-DISEASE ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor- and hepatocyte growth factor in postmenopausal women
    (TAYLOR & FRANCIS LTD, 2009) YOLDEMİR, AHMET TEVFİK; Oezer, K. Sezer; Erenus, M.; Yoldemir, T.
    Objective To investigate the effect of tibolone and hormone treatment on serum C-reactive protein, tumor necrosis factor- and hepatocyte growth factor as independent markers of cardiovascular disease. Design Ninety-five normotensive and healthy postmenopausal women with no systemic or cardiac disease who attended the Marmara University Menopause Outpatient Clinic were included in this study. The women were assigned into three groups. The women who accepted hormone replacement therapy were randomized to two groups. Group 1 received 0.625mg conjugated estrogen (CE)+2.5mg medroxyprogesterone acetate (MPA)/day. Group 2 received 2.5mg tibolone/day. Group 3 was the control group consisting of women who did not want hormone replacement therapy. Serum samples were measured for highly specific C-reactive protein, tumor necrosis factor and hepatocyte growth factor before the treatment and after 6 months of therapy. Values at the end of the 6th month and baseline were compared. Results The increase in C-reactive protein and the decrease in tumor necrosis factor- levels demonstrated at the end of treatment were statistically significant, in both the hormone therapy and tibolone groups. However, the decrease in hepatocyte growth factor was significant only in the tibolone group. Conclusions The positive impact of both tibolone and hormone therapy on inflammatory markers appears to be protective against cardiovascular diseases. However, the clinical implications of these findings are yet to be evaluated in large clinical trials.
  • No Thumbnail Available
    PublicationMetadata only
    The association between sexual dysfunction and metabolic syndrome among Turkish postmenopausal women
    (TAYLOR & FRANCIS LTD, 2019) YOLDEMİR, AHMET TEVFİK; Yoldemir, T.; Garibova, N.; Atasayan, K.
    Objective: The aim of this study is to determine the association between sexual dysfunction and metabolic syndrome (MS) among Turkish postmenopausal women Methods: In total, 290 postmenopausal women between the ages of 50 and 70 years and 265 premenopausal women between the ages of 30 and 49 years who applied to Menopause and Gynecology Clinics at Marmara University-affiliated Pendik Education and Research Hospital, Istanbul, Turkey were included in this prospective survey. Sexual function was assessed using the Female Sexual Function Index (FSFI). A FSFI total score of Results: Sexual dysfunction prevalence among postmenopausal women was 64.6% in relation to 42.1% in premenopausal women (p = 0.001). MS prevalence was 13.5% among premenopausal women and 15.5% among postmenopausal women (p = 0.57). The total FSFI score and each score in the desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia domains of the FSFI did not differ between premenopausal and postmenopausal women, regarding the MS status. In the premenopausal group, 45.7% of women without MS and 37% of women with MS had lower sexual dysfunction (p = 0.40); whereas in the postmenopausal group, 62.2% of women without MS and 77.4% of women with MS had lower sexual function (p = 0.22). Conclusion: In our study population, the rate of sexual dysfunction increased in postmenopausal women in contrast to premenopausal women. The MS status did not make a difference in terms of sexual dysfunction either in premenopausal or postmenopausal women. Since our survey was conducted in a tertiary medical center which gave medical care service to women from middle and low socioeconomic classes, our results should be confirmed by a large multicenter survey enrolling women from all different socioeconomic classes.
  • No Thumbnail Available
    PublicationMetadata only
    The prevalence of metabolic syndrome in pre- and post-menopausal women attending a tertiary clinic in Turkey
    (ELSEVIER SCIENCE BV, 2012) YOLDEMİR, AHMET TEVFİK; Yoldemir, Tevfik; Erenus, Mithat
    Objective: To determine the prevalence of metabolic syndrome among pre- and post-menopausal women attending a tertiary clinic in Turkey. Study design: This is a cross-sectional study consisting of one hundred and eighty healthy postmenopausal women and fifty-three healthy premenopausal women evaluated for presence or absence of metabolic syndrome. The t test and Fischer exact test were used for continuous variables and chi-square test was used for categorical variables. Results: The prevalence of metabolic syndrome among pre-menopausal women was 15.09% according to NCEP criteria. The prevalence of metabolic syndrome among postmenopausal women was 19.44% according to NCEP criteria. There was no significant difference in the prevalence of metabolic syndrome between premenopausal and postmenopausal women in our study population. Conclusion: There was no significant difference in the prevalence of metabolic syndrome between premenopausal and postmenopausal women attending a tertiary clinic in Turkey. (C) 2012 Elsevier Ireland Ltd. All rights reserved.